Immunizations with DCs loaded with Eph-A2 derived peptides inhibit the growth of both EphA2-positive and EphA2-negative tumors. (A) C57BL/6 mice received 1 × 105 MCA205 cells s.c. on day 0. These animals were then immunized with 1 × 106 DCs loaded with the indicated peptides on days 3, 10. Tumor growth was monitored for 28 days following the tumor inoculation (N = 5/group). P < 0.05 for both mEphA2671–679/30–44 and mEphA2682–689/30–44 treatments in comparison to OVA control for the tumor based on a two-tailed Student-t test (*). (B) C57BL/6 mice received s.c. pre-immunizations with 1 × 106 DCs loaded with either mEphA2671–679, mEphA2682–689, mEphA230–44 or control OVA257–264 on days -14 and -7 (N = 5 /group), followed by s.c. challenge with 5 × 104 B16 melanoma cells on day 0. On day 14, the size of tumors and the number of animals that had measurable tumors were assessed. P < 0.01 for EphA2671–679, EphA2682–689 and EphA230–44 treatments in comparison to OVA257–264 treated group (*).